
Ginkgo Bioworks is a leading horizontal platform for cell programming that provides flexible, end-to-end synthetic biology services across diverse markets including food, agriculture, pharmaceuticals, and industrial chemicals. The company leverages a $1 billion R&D platform combining highly automated labs, AI tools, and deep scientific expertise to accelerate research and development projects. Ginkgo offers custom R&D solutions, packaged services, and low-cost R&D tools to solve complex biological challenges, enabling partners to program cells like computers for applications in agriculture, biopharma, biosecurity, government, and industrial biotechnology. Their platform supports any scale and challenge, positioning Ginkgo as a key innovation partner in synthetic biology with broad market reach and advanced technological capabilities.

Ginkgo Bioworks is a leading horizontal platform for cell programming that provides flexible, end-to-end synthetic biology services across diverse markets including food, agriculture, pharmaceuticals, and industrial chemicals. The company leverages a $1 billion R&D platform combining highly automated labs, AI tools, and deep scientific expertise to accelerate research and development projects. Ginkgo offers custom R&D solutions, packaged services, and low-cost R&D tools to solve complex biological challenges, enabling partners to program cells like computers for applications in agriculture, biopharma, biosecurity, government, and industrial biotechnology. Their platform supports any scale and challenge, positioning Ginkgo as a key innovation partner in synthetic biology with broad market reach and advanced technological capabilities.
Core offering: Horizontal synthetic biology platform providing automated foundry labs, design tools, and R&D services
Headquarters & founding: Founded 2008; headquartered in Boston, Massachusetts
Scale: Platform includes >$1B invested in lab infrastructure and ~787 employees
Markets served: Food, agriculture, biopharma, industrial biotech, biosecurity
Total funding (reported): USD 1,575,400,000 (last funding date 2024-04-10)
Biological engineering and synthetic biology enabling bespoke microbes, cell lines, and bio-based products across multiple industries.
2008
Synthetic biology / Biotechnology
9000000
Series A reported at $9M
45000000
Series B reported at $45M
100000000
Series C reported at $100M
275000000
Series D reported at $275M
290000000
Series E reported at $290M